Literature DB >> 26196232

Innate and adaptive cellular phenotypes contributing to pulmonary disease in mice after respiratory syncytial virus immunization and infection.

Young-Tae Lee1, Ki-Hye Kim1, Hye Suk Hwang2, Youri Lee2, Young-Man Kwon1, Eun-Ju Ko2, Yu-Jin Jung2, Yu-Na Lee1, Min-Chul Kim3, Sang-Moo Kang4.   

Abstract

Respiratory syncytial virus (RSV) is the major leading cause of infantile viral bronchiolitis. However, cellular phenotypes contributing to the RSV protection and vaccine-enhanced disease remain largely unknown. Upon RSV challenge, we analyzed phenotypes and cellularity in the lung of mice that were naïve, immunized with formalin inactivated RSV (FI-RSV), or re-infected with RSV. In comparison with naïve and live RSV re-infected mice, the high levels of eosinophils, neutrophils, plasmacytoid and CD11b(+) dendritic cells, and IL-4(+) CD4(+) T cells were found to be contributing to pulmonary inflammation in FI-RSV immune mice despite lung viral clearance. Alveolar macrophages appeared to play differential roles in protection and inflammation upon RSV infection of different RSV immune mice. These results suggest that multiple innate and adaptive immune components differentially contribute to RSV disease and inflammation.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alveolar macrophages; Clodronate liposome; Formalin-inactivated RSV; Respiratory syncytial virus (RSV); Vaccine

Mesh:

Substances:

Year:  2015        PMID: 26196232      PMCID: PMC4619147          DOI: 10.1016/j.virol.2015.07.001

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  44 in total

1.  Antigen presentation in the lung.

Authors:  P G Holt
Journal:  Am J Respir Crit Care Med       Date:  2000-10       Impact factor: 21.405

2.  Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine.

Authors:  H W Kim; J G Canchola; C D Brandt; G Pyles; R M Chanock; K Jensen; R H Parrott
Journal:  Am J Epidemiol       Date:  1969-04       Impact factor: 4.897

3.  An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine.

Authors:  A Z Kapikian; R H Mitchell; R M Chanock; R A Shvedoff; C E Stewart
Journal:  Am J Epidemiol       Date:  1969-04       Impact factor: 4.897

4.  Visualization and characterization of respiratory syncytial virus F-specific CD8(+) T cells during experimental virus infection.

Authors:  J Chang; A Srikiatkhachorn; T J Braciale
Journal:  J Immunol       Date:  2001-10-15       Impact factor: 5.422

5.  Depletion of alveolar macrophages exerts protective effects in pulmonary tuberculosis in mice.

Authors:  J C Leemans; N P Juffermans; S Florquin; N van Rooijen; M J Vervoordeldonk; A Verbon; S J van Deventer; T van der Poll
Journal:  J Immunol       Date:  2001-04-01       Impact factor: 5.422

6.  The attachment (G) glycoprotein of respiratory syncytial virus contains a single immunodominant epitope that elicits both Th1 and Th2 CD4+ T cell responses.

Authors:  S M Varga; E L Wissinger; T J Braciale
Journal:  J Immunol       Date:  2000-12-01       Impact factor: 5.422

7.  IL-13 is sufficient for respiratory syncytial virus G glycoprotein-induced eosinophilia after respiratory syncytial virus challenge.

Authors:  Teresa R Johnson; Robert A Parker; Joyce E Johnson; Barney S Graham
Journal:  J Immunol       Date:  2003-02-15       Impact factor: 5.422

8.  Activated mouse eosinophils protect against lethal respiratory virus infection.

Authors:  Caroline M Percopo; Kimberly D Dyer; Sergei I Ochkur; Janice L Luo; Elizabeth R Fischer; James J Lee; Nancy A Lee; Joseph B Domachowske; Helene F Rosenberg
Journal:  Blood       Date:  2013-12-02       Impact factor: 22.113

9.  Baculovirus-expressed virus-like particle vaccine in combination with DNA encoding the fusion protein confers protection against respiratory syncytial virus.

Authors:  Jong Seok Lee; Young-Man Kwon; Hye Suk Hwang; Yu-Na Lee; Eun-Ju Ko; Si-Eun Yoo; Min-Chul Kim; Ki-Hye Kim; Min Kyoung Cho; Young-Tae Lee; You Ri Lee; Fu-Shi Quan; Sang-Moo Kang
Journal:  Vaccine       Date:  2014-08-27       Impact factor: 3.641

10.  Alveolar macrophage-derived type I interferons orchestrate innate immunity to RSV through recruitment of antiviral monocytes.

Authors:  Michelle Goritzka; Spyridon Makris; Fahima Kausar; Lydia R Durant; Catherine Pereira; Yutaro Kumagai; Fiona J Culley; Matthias Mack; Shizuo Akira; Cecilia Johansson
Journal:  J Exp Med       Date:  2015-04-20       Impact factor: 14.307

View more
  11 in total

1.  Novel recombinant DNA vaccine candidates for human respiratory syncytial virus: Preclinical evaluation of immunogenicity and protection efficiency.

Authors:  Mohamed A Farrag; Haitham M Amer; Peter Öhlschläger; Maaweya E Hamad; Fahad N Almajhdi
Journal:  Hum Vaccin Immunother       Date:  2017-03-08       Impact factor: 3.452

2.  Cellular Immune Correlates Preventing Disease Against Respiratory Syncytial Virus by Vaccination with Virus-Like Nanoparticles Carrying Fusion Proteins.

Authors:  Young-Tae Lee; Eun-Ju Ko; Ki-Hye Kim; Hye Suk Hwang; Youri Lee; Young-Man Kwon; Min-Chul Kim; Yu-Na Lee; Yu-Jin Jung; Sang-Moo Kang
Journal:  J Biomed Nanotechnol       Date:  2017-01       Impact factor: 4.099

3.  Soluble F proteins exacerbate pulmonary histopathology after vaccination upon respiratory syncytial virus challenge but not when presented on virus-like particles.

Authors:  Youri Lee; Young-Tae Lee; Eun-Ju Ko; Ki-Hye Kim; Hye Suk Hwang; Soojin Park; Young-Man Kwon; Sang Moo Kang
Journal:  Hum Vaccin Immunother       Date:  2017-11-02       Impact factor: 3.452

4.  New Look at RSV Infection: Tissue Clearing and 3D Imaging of the Entire Mouse Lung at Cellular Resolution.

Authors:  Maxence Frétaud; Delphyne Descamps; Daphné Laubreton; Marie-Anne Rameix-Welti; Jean-François Eléouët; Thibaut Larcher; Marie Galloux; Christelle Langevin
Journal:  Viruses       Date:  2021-01-28       Impact factor: 5.048

5.  Respiratory Syncytial Virus Aggravates Renal Injury through Cytokines and Direct Renal Injury.

Authors:  Songhui Zhai; Lijuan Hu; Lin Zhong; Yannan Guo; Liqun Dong; Ruizhen Jia; Zheng Wang
Journal:  Front Cell Infect Microbiol       Date:  2016-09-30       Impact factor: 5.293

6.  Heat-killed Lactobacillus casei confers broad protection against influenza A virus primary infection and develops heterosubtypic immunity against future secondary infection.

Authors:  Yu-Jin Jung; Young-Tae Lee; Vu Le Ngo; Young-Hee Cho; Eun-Ju Ko; Sung-Moon Hong; Ki-Hye Kim; Ji-Hun Jang; Joon-Suk Oh; Min-Kyung Park; Cheol-Hyun Kim; Jun Sun; Sang-Moo Kang
Journal:  Sci Rep       Date:  2017-12-12       Impact factor: 4.379

Review 7.  The Relationship between Gut Microbiota and Respiratory Tract Infections in Childhood: A Narrative Review.

Authors:  Daniele Zama; Camilla Totaro; Lorenzo Biscardi; Alessandro Rocca; Silvia Turroni; Patrizia Brigidi; Marcello Lanari
Journal:  Nutrients       Date:  2022-07-21       Impact factor: 6.706

8.  Vaccination by microneedle patch with inactivated respiratory syncytial virus and monophosphoryl lipid A enhances the protective efficacy and diminishes inflammatory disease after challenge.

Authors:  Soojin Park; Youri Lee; Young-Man Kwon; Young-Tae Lee; Ki-Hye Kim; Eun-Ju Ko; Jae Hwan Jung; Manki Song; Barney Graham; Mark R Prausnitz; Sang-Moo Kang
Journal:  PLoS One       Date:  2018-10-26       Impact factor: 3.240

9.  Impaired tumor necrosis factor-α secretion by CD4 T cells during respiratory syncytial virus bronchiolitis associated with recurrent wheeze.

Authors:  Maleewan Kitcharoensakkul; Leonard B Bacharier; Huiqing Yin-Declue; Jonathan S Boomer; Geneline Sajol; Marilyn K Leung; Brad Wilson; Kenneth B Schechtman; John P Atkinson; Jonathan M Green; Mario Castro
Journal:  Immun Inflamm Dis       Date:  2020-01-04

10.  Contribution of NKT cells to the immune response and pathogenesis triggered by respiratory viruses.

Authors:  Emma Rey-Jurado; Karen Bohmwald; Nicolás M S Gálvez; Daniela Becerra; Steven A Porcelli; Leandro J Carreño; Alexis M Kalergis
Journal:  Virulence       Date:  2020-12       Impact factor: 5.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.